Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

被引：13

作者：

Zeidan, Amer M. ^{[1
,2
]}

Borate, Uma ^{[3
]}

Pollyea, Daniel A. ^{[4
]}

Brunner, Andrew M. ^{[5
]}

Roncolato, Fernando ^{[6
]}

Garcia, Jacqueline S. ^{[7
]}

Filshie, Robin J. ^{[8
]}

Odenike, Olatoyosi ^{[9
,10
]}

Watson, Anne-Marie ^{[11
]}

Krishnadasan, Ravi ^{[12
]}

Bajel, Ashish ^{[13
,14
]}

Naqvi, Kiran ^{[15
]}

Zha, Jiuhong ^{[16
]}

Hogdal, Leah ^{[16
]}

Zhou, Ying ^{[16
]}

Hoffman, David ^{[16
]}

Kye, Steve ^{[16
]}

Garcia-Manero, Guillermo ^{[17
]}

机构：

[1] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Knight Canc Inst, Portland, OR 97201 USA

[4] Univ Colorado, Dept Hematol, Aurora, CO USA

[5] Massachusetts Gen Hosp, Ctr Leukemia, Boston, MA 02114 USA

[6] Univ New South Wales, Dept Hematol, Sydney, NSW, Australia

[7] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[8] St Vincents Hosp Melbourne, Dept Hematol, Melbourne, Vic, Australia

[9] Univ Chicago Med, Chicago, IL USA

[10] Comprehens Canc Ctr, Chicago, IL USA

[11] Liverpool Hosp, Dept Haematol, Liverpool, Merseyside, Australia

[12] Univ Arizona, Canc Ctr, Tucson, AZ USA

[13] Peter MacCallum Canc Ctr, Dept Clin Haematol, Melbourne, Vic, Australia

[14] Royal Melbourne Hosp, Melbourne, Vic, Australia

[15] Genentech Inc, San Francisco, CA 94080 USA

[16] AbbVie Inc, N Chicago, IL USA

[17] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145646

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

537

引用

页数：6

共 50 条

[1] Results of a phase 1 trial of azacitidine with venetoclax in relapsed/refractory higherrisk myelodysplastic syndrome (MDS).
Desikan, Sai Prasad
Montalban-Bravo, Guillermo
Ohanian, Maro
Daver, Naval Guastad
Kadia, Tapan M.
Venugopal, Sangeetha
Chien, Kelly Sharon
Kanagal-Shamanna, Rashmi
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
Zeidan, Amer M.
Borate, Uma
Pollyea, Daniel A.
Brunner, Andrew M.
Roncolato, Fernando
Garcia, Jacqueline S.
Filshie, Robin
Odenike, Olatoyosi
Watson, Anne Marie
Krishnadasan, Ravitharan
Bajel, Ashish
Naqvi, Kiran
Zha, Jiuhong
Cheng, Wei-Han
Zhou, Ying
Hoffman, David
Harb, Jason G.
Potluri, Jalaja
Garcia-Manero, Guillermo
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (02) : 272 - 281
[3] A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome
Zeidan, Amer M.
Pollyea, Daniel A.
Garcia, Jacqueline S.
Brunner, Andrew
Roncolato, Fernando
Borate, Uma
Odenike, Olatoyosi
Bajel, Ashish R.
Watson, Anne Marie
Gotze, Katharina
Nolte, Florian
Tan, Peter T.
Hong, Wan-Jen
Dunbar, Martin
Zhou, Ying
Gressick, Lori
Ainsworth, William
Harb, Jason
Salem, Ahmed Hamed
Hayslip, John
Swords, Ronan
Garcia-Manero, Guillermo
BLOOD, 2019, 134
[4] Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax
Niswander, Lisa M.
Chung, Perry
Diorio, Caroline
Tasian, Sarah K.
HAEMATOLOGICA, 2023, 108 (11) : 3142 - 3147
[5] Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia
Bouligny I.M.
Murray G.
Doyel M.
Patel T.
Boron J.
Tran V.
Gor J.
Hang Y.
Alnimer Y.
Ho T.
Zacholski K.
Venn C.
Wages N.A.
Grant S.
Maher K.R.
Medical Oncology, 41 (3)
[6] Azacitidine for the treatment of relapsed and refractory AML in older patients
Itzykson, Raphael
Thepot, Sylvain
Berthon, Celine
Delaunay, Jacques
Bouscary, Didier
Cluzeau, Thomas
Turlure, Pascal
Prebet, Thomas
Dartigeas, Caroline
Marolleau, Jean-Pierre
Recher, Christian
Plantier, Isabelle
Stamatoullas, Aspasia
Devidas, Alain
Taksin, Anne-Laure
Guieze, Romain
Caillot, Denis
Vey, Norbert
Ades, Lionel
Ifrah, Norbert
Dombret, Herve
Fenaux, Pierre
Gardin, Claude
LEUKEMIA RESEARCH, 2015, 39 (02) : 124 - 130
[7] A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
Bouligny, Ian M.
Montalban-Bravo, Guillermo
Sasaki, Koji
Daver, Naval
Jabbour, Elias
Valero, Yesid Alvarado
Dinardo, Courtney D.
Ravandi, Farhad
Pemmaraju, Naveen
Kadia, Tapan M.
Masarova, Lucia
Takahashi, Koichi
Andreeff, Michael
Bazinet, Alexandre
Yang, Hui
Kanagal-Shamanna, Rashmi
Pierce, Sherry
Meyer, Meghan Anne
Huang, Xuelin
Garcia-Manero, Guillermo
BLOOD, 2024, 144 : 3212 - 3214
[8] Venetoclax in combination with azacitidine or decitabine in relapsed/refractory acute myeloid leukemia
Che, Yue
Tan, Wanqing
Liu, Ying
Liu, Haitao
Li, Lanlan
Qin, Fangmei
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2024, 23 (01) : 209 - 214
[9] Azacitidine for the treatment of myelodysplastic syndrome
Cataldo, Vince D.
Cortes, Jorge
Quintas-Cardama, Alfonso
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (07) : 875 - 884
[10] A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
Desikan, Sai Prasad Prasad
Montalban-Bravo, Guillermo
Ohanian, Maro
Daver, Naval
Yilmaz, Musa
Konopleva, Marina
Kadia, Tapan M.
Venugopal, Sangeetha
Schneider, Heather
Chien, Kelly S.
Kanagal-Shamanna, Rashmi
Kantarjian, Hagop
Garcia-Manero, Guillermo
BLOOD, 2021, 138 : 3704 - +

← 1 2 3 4 5 →